🧬 TargED Biopharmaceuticals has dosed the first patient in its Phase 1/2 proof-of-concept study of TGD001.
🩸 TGD001 is a targeted thrombolytic: a drug designed to dissolve blood clots by breaking down von Willebrand factor and fibrin. The study looks at immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare and serious condition in which small blood clots damage the organs, and at other thrombotic microangiopathies. There are currently no approved drugs that break down existing clots in these patients.
The study can include up to 70 patients at sites in Europe and the US, and first data are expected in 2027. Earlier, TGD001 showed a favourable safety profile in healthy volunteers, and a study in acute ischemic stroke is ongoing.